Research Perspective Volume 2, Issue 4 pp 224—230
How to track cellular aging of mesenchymal stromal cells?
- 1 Helmholtz Institute for Biomedical Engineering, Department of Cell Biology, RWTH Aachen University Medical School, 52074 Aachen, Germany
- 2 Department of Medicine V, University of Heidelberg, 69120 Heidelberg, Germany
- 3 Institute for Biomedical Aging Research, Rennweg 10, 6020 Innsbruck, Austria
- 4 Reference and translational center for cardiac stem cell therapy, University of Rostock, 18057 Rostock, Germany
- 5 Stem Cell Research Unit Graz, Medical University of Graz, 8036 Graz, Austria
received: March 26, 2010 ; accepted: April 5, 2010 ; published: April 8, 2010 ;https://doi.org/10.18632/aging.100136
How to Cite
Mesenchymal stromal cells (MSC) are currently tested in a large number of clinical trials and raise high hope in regenerative medicine. These cells have to be expanded in vitro before transplantation and several studies demonstrated that long-term culture evokes continuous changes in MSC: proliferation rate decays, the cell size increases, differentiation potential is affected, chromosomal instabilities may arise and molecular changes are acquired. Long-term culture of cell preparations might also have therapeutic consequences, although this has hardly been addressed in ongoing trials so far. Reliable therapeutic regimens necessitate quality control of cellular products. This research perspective summarizes available methods to track cellular aging of MSC. We have demonstrated that gene expression changes and epigenetic modifications are continuously acquired during replicative senescence. Molecular analysis of a suitable panel of genes might provide a robust tool to assess efficiency and safety of long-term expansion.